정밀 종양학 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 제품 유형별, 암 유형별, 최종사용자 지역별, 경쟁별 세분화(2020-2030년)

The Global Precision Oncology Market , valued at USD 99.45 Billion in 2024, is projected to experience a CAGR of 9.12% to reach USD 167.87 Billion by 2030. Precision oncology tailors cancer treatment based on an individual's tumor genetic and molecular profiles, aiming for therapies that are more effective and reduce adverse effects by targeting specific cancer cell vulnerabilities. The market's growth is fundamentally driven by continuous advancements in genomic sequencing technologies, which enable comprehensive molecular profiling, alongside a deepening understanding of cancer genomics. Additionally, the escalating global prevalence of cancer significantly increases the demand for precise and individualized treatment options.

Key Market Drivers

The global precision oncology market is significantly influenced by two primary drivers: the escalating worldwide burden of cancer and continuous technological progress in genomic sequencing and molecular diagnostics. The rising global cancer incidence and mortality rates present a critical and expanding patient population in need of more effective and individualized therapeutic strategies.

Key Market Challenges

The complex interaction of high costs associated with developing and administering personalized therapies, coupled with persistent barriers in patient access and reimbursement, significantly impedes the growth of the Global Precision Oncology Market. Despite the inherent benefits of tailored treatments, the substantial financial burden often deters widespread adoption, limiting the ability of eligible patients to receive these advanced solutions. This challenge is further exacerbated by operational inefficiencies and a limited understanding of biomarker strategies among various healthcare stakeholders.

Key Market Trends

Multi-omics integration for comprehensive patient profiling represents a pivotal shift towards a more holistic understanding of cancer. This trend involves combining data from genomics, proteomics, transcriptomics, and metabolomics to create an exhaustive molecular blueprint of an individual's tumor. Such detailed profiling enables clinicians to identify complex disease mechanisms, pinpoint actionable targets with greater precision, and predict therapeutic responses more effectively, ultimately leading to highly individualized treatment strategies.

Key Market Players

• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Qiagen N.V.
• Illumina, Inc.
• Laboratory Corporation Of America Holding
• Exact Sciences Corporation
• Rain Oncology Inc.
• Strata Oncology, Inc.
• Xilis Inc.
• Variantyx, Inc.

Report Scope:

In this report, the Global Precision Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Oncology Market , By Product Type:

• Diagnostics
• Therapeutics

Precision Oncology Market , By Cancer Type:

• Breast Cancer
• Cervical Cancer
• Prostate Cancer
• Lung Cancer

Precision Oncology Market , By End User:

• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Healthcare Data Companies

Precision Oncology Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Precision Oncology Market .

Available Customizations:

Global Precision Oncology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Oncology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Diagnostics, Therapeutics)
  • 5.2.2. By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer)
  • 5.2.3. By End User (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Healthcare Data Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Precision Oncology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Cancer Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Oncology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Cancer Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Precision Oncology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Cancer Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Precision Oncology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Cancer Type
      • 6.3.3.2.3. By End User

7. Europe Precision Oncology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Cancer Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Precision Oncology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Cancer Type
      • 7.3.1.2.3. By End User
  • 7.3.2. France Precision Oncology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Cancer Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Precision Oncology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Cancer Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Precision Oncology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Cancer Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Precision Oncology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Cancer Type
      • 7.3.5.2.3. By End User

8. Asia Pacific Precision Oncology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Cancer Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Oncology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Cancer Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Precision Oncology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Cancer Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Precision Oncology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Cancer Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Precision Oncology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Cancer Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Precision Oncology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Cancer Type
      • 8.3.5.2.3. By End User

9. Middle East & Africa Precision Oncology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Cancer Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Precision Oncology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Cancer Type
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Precision Oncology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Cancer Type
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Precision Oncology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Cancer Type
      • 9.3.3.2.3. By End User

10. South America Precision Oncology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Cancer Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Precision Oncology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Cancer Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Precision Oncology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Cancer Type
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Precision Oncology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Cancer Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Oncology Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Invitae Corporation
• 15.3. Qiagen N.V.
• 15.4. Illumina, Inc.
• 15.5. Laboratory Corporation Of America Holding
• 15.6. Exact Sciences Corporation
• 15.7. Rain Oncology Inc.
• 15.8. Strata Oncology, Inc.
• 15.9. Xilis Inc.
• 15.10. Variantyx, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer